{"schema_version":"secwatch.filing_event.v1","accession":"0001108205-24-000061","form_type":"8-K","ticker":"CRIS","cik":"0001108205","company_name":"CURIS INC","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.194558+00:00","generated_at":"2026-05-31T13:38:40.971333+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL","bullets":["Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.","Cash, equivalents and investments $28.4M; expected to fund operations into Q1 2025.","EC granted Orphan Drug Designation to emavusertib for treatment of primary CNS lymphoma.","Initial data for 15-20 R/R PCNSL patients expected late 2024; ASH presentation planned.","Updated TakeAim Leukemia data and frontline triplet combo safety data due late 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001108205-24-000061","json":"https://secwatch.observer/filing/0001108205-24-000061.json","markdown":"https://secwatch.observer/filing/0001108205-24-000061.md","text":"https://secwatch.observer/filing/0001108205-24-000061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/0001108205-24-000061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1108205/000110820524000061/cris-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:38:40.971333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}